Treatment and outcomes of post‐transplant lymphoproliferative disease: A single institution study

Abstract

Post-transplant lymphoproliferative disorders (PTLD) complicate up to 10% of solid organ transplants. This retrospective study was conducted to review the PTLD experience among 2,300 recipients of solid organ or allogeneic bone marrow transplants from a single institution. Twenty-seven cases of PTLD were identified, leading to an overall incidence of 1.2%. Polymorphic B cell hyperplasia/lymphoma was the most common type. The median time to development of PTLD was 8.4 months. Ten patients had localized (stage I or II) disease, and 12 patients presented with B symptoms. Nine patients each were treated with systemic chemotherapy or surgical resection as part of the initial therapy. After a median follow-up duration of 2.6 years, the median survival has not been reached. There were no late relapses of PTLD, and 17 patients remain alive. Age, sex, organ source, LDH, stage, presence of extranodal disease, or presentation with B symptoms did not influence overall survival when examined by Cox proportional hazard model. Thirteen patients retained their graft function throughout PTLD treatment. This study confirms the ability to treat a significant proportion of PTLD patients with chemotherapy or surgical resection (depending on presentation), without sacrificing graft function in those receiving chemotherapy. Am. J. Hematol. 82:208-214, 2007. V V C 2006 Wiley-Liss, Inc.

Post-transplantation lymphoproliferative disorder (PTLD) twenty years after heart transplantation: a case report and review of the literature

“…In the same report, EBV was present in all the biopsy specimens tested, while EBV was not detected in our patient's biopsy. Another single institution report estimated the incidence of PTLD after heart transplant at 7.8%, with the longest interval to PTLD development being 10.7 months [35]. To the best of our knowledge, the present case exhibits one of the longest intervals to PTLD development after a heart transplant.…”

Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment

“…In 1 case the neoplasm was synchronous. Buadi et al [49] reported 3 patients with additional cancers (11%): 2 at 2 years and another at 6 months after the diagnosis of PTLD. This suggests monitoring the patients not only for relapse of PTLD, opportunistic infection and organ rejection, but also for other neoplastic diseases.…”

Hepatitis C Virus Infection Can Affect Lymphoproliferative Disorders Only as a Cofactor for Epstein-Barr Virus in Liver Transplant Recipients: PTLD.Int Survey

“…A total of 212 cases of PTLD LT patients were included in the analysis; of whom 68 23 16 (7.5) 5 (7.4) 11 (7.6) 3 Capello et al 24 14 (6.6) 8 (11.8) 6 (4.2) 4 Norin et al 25 12 (5.7) 1 (1.5) 11 (7.6) 5 He´Zode et al 26 6 (2.8) 4 (5.9) 2 (1.4) 6 Buadi et al 27 4 (1.9) 2 (2.9) 2 (1.4) 7 Zimmermann et al 28 11 (5.2) 1 (1.5) 10 (6.9) 8 Lorenzini et al 29 4 (1.9) 1 (1.5) 3 (2.1) 9 Timurağaoğlu et al 30 1 (0.5) 0 1 (0.7)…”